Menu
Search
|

Menu

Close
X

BioXcel Therapeutics Inc BTAI.OQ (NASDAQ Stock Exchange Capital Market)

11.01 USD
-- (--)
As of Jul 18
chart
Previous Close 11.01
Open --
Volume --
3m Avg Volume 15,335
Today’s High --
Today’s Low --
52 Week High 14.28
52 Week Low 6.89
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.374
FY17
-0.276
FY16
-0.070
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Peter Mueller
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Vimal Mehta
President, Chief Executive Officer, Secretary, Director, Since 2017
Salary: $147,000.00
Bonus: --
Richard Steinhart
Chief Financial Officer, Since 2017
Salary: $30,000.00
Bonus: --
Frank Yocca
Chief Scientific Officer, Since 2017
Salary: $168,000.00
Bonus: --
Chids Mahadevan
Vice President - Finance, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

780 E Main St
BRANFORD   CT   06405-2918

Phone: +1203.6438060

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

SPONSORED STORIES